Skip to content

Dermacyd in Odor Reducing.

Single Center, Open, Cross-over, Phase III Study for Comparative Evaluation of Safety Use and Efficacy in the Odor Reduce and Vaginal Moisturize Increase for Intimates Use Products Dermacyd Femina Delicata, Dermacyd Femina Breeze, Dermacyd Teen Sweet Flower, Dermacyd Teen Fresh Mix and Dermacyd Femina Comparing to the Control Product Glycerine Vegetal Soap Granado Traditional.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01158365
Enrollment
230
Registered
2010-07-08
Start date
2010-07-31
Completion date
2010-12-31
Last updated
2011-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hygiene

Brief summary

Primary Objective: \- To prove the efficacy superiority in reducing the genital odor and increase hydration in mucosa genital comparing the use of Dermacyd (different fragrances) and Glycerine Vegetal Soap Granado Traditional Secondary Objective: \- To evaluate the safety in normal conditions of use, verifying clinical signs and lab exams.

Interventions

Route of administration: local

Route of administration: local

Sponsors

Sanofi
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Perfect mucosa in the product analysis region * Volunteers with active sexual life: normal Papanicolau test performed less than one year is mandatory * Bacterioscopy describing the vaginal flora * Negative Trichomonas vaginalis test * Negative Whiff test * Willingness in using preservative in the sexual intercourse during the study period * Use the same category cosmetics products * Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion

Exclusion criteria

* Use of antiinflammatory / immunosuppression / antihistaminic drugs * Atopic or allergy history to cosmetic products * Active cutaneous disease (local and/or disseminated) in the evaluated area * Disease which can cause immunosuppression, such as diabetes, HIV, etc. * Endocrine pathology such as thyroid disease, ovarian or adrenal gland disturbs * Intense solar exposure (to get a tan) during the 15 days before the evaluation * Gynecologic treatment until four weeks before the evaluation * Any vaginal infection detected during the inclusion * Other conditions considered by the investigator as reasonable for exclude the patient in the study. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Reduction of genital odor and increase hydration in genital mucosaFrom the treatment start to the end of the study (day 67)Patient's questionnaire will be completed at V1, V2 and V4. Reduction of vaginal odor, increase in the moisture area, and perception about some items like foam, facility of rinsing, final touch of the mucosa, final fragrance, and cleaning sensation will be rated on a 5-point scale.

Secondary

MeasureTime frameDescription
Evaluation of the integrity of the mucosaFrom the treatment start to the end of the study (day 67)Onset of erythema, edema, scaling, blisters or other clinical sign will be evaluated.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026